These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 24672981)

  • 1. [New insights into adipose cell biology].
    Burcelin R
    Bull Acad Natl Med; 2013 Jan; 197(1):79-92. PubMed ID: 24672981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gut microbiota controls adipose tissue expansion, gut barrier and glucose metabolism: novel insights into molecular targets and interventions using prebiotics.
    Geurts L; Neyrinck AM; Delzenne NM; Knauf C; Cani PD
    Benef Microbes; 2014 Mar; 5(1):3-17. PubMed ID: 23886976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metagenome and metabolism: the tissue microbiota hypothesis.
    Burcelin R; Serino M; Chabo C; Garidou L; Pomié C; Courtney M; Amar J; Bouloumié A
    Diabetes Obes Metab; 2013 Sep; 15 Suppl 3():61-70. PubMed ID: 24003922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New physiological effects of the incretin hormones GLP-1 and GIP.
    Asmar M
    Dan Med Bull; 2011 Feb; 58(2):B4248. PubMed ID: 21299928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Managing the manager: gut microbes, stem cells and metabolism.
    Serino M; Blasco-Baque V; Nicolas S; Burcelin R
    Diabetes Metab; 2014 Jun; 40(3):186-90. PubMed ID: 24462190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Newly approved and promising antidiabetic agents.
    Combettes M; Kargar C
    Therapie; 2007; 62(4):293-310. PubMed ID: 17983555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gut microbiota and energy balance: role in obesity.
    Blaut M
    Proc Nutr Soc; 2015 Aug; 74(3):227-34. PubMed ID: 25518735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Physiological patterns of intestinal microbiota. The role of dysbacteriosis in obesity, insulin resistance, diabetes and metabolic syndrome].
    Halmos T; Suba I
    Orv Hetil; 2016 Jan; 157(1):13-22. PubMed ID: 26708682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immuno-microbiota cross and talk: the new paradigm of metabolic diseases.
    Burcelin R; Garidou L; Pomié C
    Semin Immunol; 2012 Feb; 24(1):67-74. PubMed ID: 22265028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The entero-insular axis in type 2 diabetes--incretins as therapeutic agents.
    Creutzfeldt W
    Exp Clin Endocrinol Diabetes; 2001; 109 Suppl 2():S288-303. PubMed ID: 11460578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GLP-1 Elicits an Intrinsic Gut-Liver Metabolic Signal to Ameliorate Diet-Induced VLDL Overproduction and Insulin Resistance.
    Khound R; Taher J; Baker C; Adeli K; Su Q
    Arterioscler Thromb Vasc Biol; 2017 Dec; 37(12):2252-2259. PubMed ID: 29074588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Failure of fat cell proliferation, mitochondrial function and fat oxidation results in ectopic fat storage, insulin resistance and type II diabetes mellitus.
    Heilbronn L; Smith SR; Ravussin E
    Int J Obes Relat Metab Disord; 2004 Dec; 28 Suppl 4():S12-21. PubMed ID: 15592481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential new approaches to modifying intestinal GLP-1 secretion in patients with type 2 diabetes mellitus: focus on bile acid sequestrants.
    Holst JJ; McGill MA
    Clin Drug Investig; 2012 Jan; 32(1):1-14. PubMed ID: 21958333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The gut-brain axis: a major glucoregulatory player.
    Burcelin R
    Diabetes Metab; 2010 Oct; 36 Suppl 3():S54-8. PubMed ID: 21211737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice.
    Cani PD; Bibiloni R; Knauf C; Waget A; Neyrinck AM; Delzenne NM; Burcelin R
    Diabetes; 2008 Jun; 57(6):1470-81. PubMed ID: 18305141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Specific Gut Microbiota Dysbiosis of Type 2 Diabetic Mice Induces GLP-1 Resistance through an Enteric NO-Dependent and Gut-Brain Axis Mechanism.
    Grasset E; Puel A; Charpentier J; Collet X; Christensen JE; Tercé F; Burcelin R
    Cell Metab; 2017 May; 25(5):1075-1090.e5. PubMed ID: 28467926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adipose tissue dysfunction in obesity, diabetes, and vascular diseases.
    Hajer GR; van Haeften TW; Visseren FL
    Eur Heart J; 2008 Dec; 29(24):2959-71. PubMed ID: 18775919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Gut microbiota and immune crosstalk in metabolic disease].
    Burcelin R
    Biol Aujourdhui; 2017; 211(1):1-18. PubMed ID: 28682223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ezetimibe stimulates intestinal glucagon-like peptide 1 secretion via the MEK/ERK pathway rather than dipeptidyl peptidase 4 inhibition.
    Chang E; Kim L; Choi JM; Park SE; Rhee EJ; Lee WY; Oh KW; Park SW; Park DI; Park CY
    Metabolism; 2015 May; 64(5):633-41. PubMed ID: 25704082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucose sensing and the pathogenesis of obesity and type 2 diabetes.
    Thorens B
    Int J Obes (Lond); 2008 Dec; 32 Suppl 6():S62-71. PubMed ID: 19079282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.